Beskrivelse
Krav
IPC-klasse
Fullmektig i Norge:
Org.nummer: 979993269
- Org.nummer:
- Foretaksnavn:
- Foretaksform:
- Næring:
-
Forretningsadresse:
Fullmektig i EP:
2015.10.02, GB 201517527
2016.04.29, GB 201607800
DAVID A REARDON ET AL: "An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma", EXPERT REVIEW OF VACCINES, vol. 12, no. 6, 1 June 2013 (2013-06-01), pages 597-615, XP055277339, GB ISSN: 1476-0584, DOI: 10.1586/erv.13.41 (B1)
J. CORRE ET AL: "Concise Review: Growth Differentiation Factor 15 in Pathology: A Clinical Role?", STEM CELLS TRANSLATIONAL MEDICINE : SCTM, vol. 2, no. 12, 1 December 2013 (2013-12-01), pages 946-952, XP055330730, Durham ISSN: 2157-6564, DOI: 10.5966/sctm.2013-0055 (B1)
JAYASHREE P JOSHI ET AL: "Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells", BIOCHEMICAL PHARMACOLOGY, ELSEVIER, US, vol. 82, no. 9, 14 July 2011 (2011-07-14), pages 1090-1099, XP028326986, ISSN: 0006-2952, DOI: 10.1016/J.BCP.2011.07.082 [retrieved on 2011-07-23] (B1)
L. ZHAO ET AL: "Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling", CANCER RESEARCH, vol. 69, no. 19, 1 October 2009 (2009-10-01), pages 7696-7703, XP055004734, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-08-4901 (B1)
MURIELLE MIMEAULT ET AL: "Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 224, no. 3, 12 May 2010 (2010-05-12), pages 626-635, XP055330227, US ISSN: 0021-9541, DOI: 10.1002/jcp.22196 (B1)
PERNELLE LAVAUD ET AL: "Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials", BMC MEDICINE, vol. 107, no. 1, 1 December 2014 (2014-12-01), page 1547, XP055330736, DOI: 10.1073/pnas.0908801107 (B1)
WO-A2-2015/108907 (B1)
SUNG JIN HUH ET AL: "Tumorigenesis and Neoplastic Progression Macrophage Inhibitory Cytokine-1 Regulates Melanoma Vascular Development", AM J PATHOL, vol. 176, 1 June 2010 (2010-06-01), pages 2948-2957, XP055330224, (B1)
Suzanne l. Topalian ET AL: "Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy", CANCER CELL, vol. 27, no. 4, 1 April 2015 (2015-04-01), pages 450-461, XP055372181, US ISSN: 1535-6108, DOI: 10.1016/j.ccell.2015.03.001 (B1)
US-A1- 2014 271 546 (B1)
WO-A1-2014/049087 (B1)
WO-A1-2015/144855 (B1)
WO-A2-2012/162561 (B1)
RUI-RU JI ET AL: "An immune-active tumor microenvironment favors clinical response to ipilimumab", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 61, no. 7, 7 December 2011 (2011-12-07), pages 1019-1031, XP035074379, ISSN: 1432-0851, DOI: 10.1007/S00262-011-1172-6 (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Varsel om betaling av første årsavgift (3319) (PTEP3356827)
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Registreringsbrev (3210) (PTEP3356827)
|
Innkommende, AR588856394
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 9. avg. år (EP) | 2024.09.16 | 3710 | Nasim Khorshidi | Betalt og godkjent |
32316587 expand_more expand_less | 2024.01.03 | 5500 | BRYN AARFLOT AS | Betalt |
Valideringsgebyr EP-patent
5500 = 1 X 5500
|